Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 4Leukemia, Myeloid, Acute 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Carcinoma, Renal Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrent Squamous Cell Lung Carcinoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Childhood Solid Tumors 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Adenocarcinoma 1Advanced Solid Tumor 1

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Adenocarcinoma × talazoparib × Clear all
NCT02282345 2022-07-06

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 14 charts
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡